1-(3,4-dimethoxyphenyl)-N-propan-2-yl-1-cyclopentanecarboxamide, also known as **N-isopropyl-1-(3,4-dimethoxyphenyl)cyclopentanecarboxamide**, is a chemical compound with potential applications in research.
Let's break down its structure and significance:
**Structure:**
* **1-cyclopentanecarboxamide:** This part indicates a cyclopentane ring (a 5-membered carbon ring) with a carboxamide group (CONH2) attached to one of the carbons.
* **1-(3,4-dimethoxyphenyl):** This part shows a phenyl ring (a 6-membered carbon ring with alternating double bonds) with two methoxy groups (OCH3) attached at the 3rd and 4th positions of the ring. This phenyl group is directly attached to the 1st carbon of the cyclopentane ring.
* **N-propan-2-yl:** This refers to an isopropyl group (CH3CHCH3) attached to the nitrogen atom of the carboxamide group.
**Importance in Research:**
While there's no widely known research on this specific compound, its structure suggests potential applications in various research areas, including:
* **Pharmacology:**
* The presence of the dimethoxyphenyl group is often found in compounds with biological activity, particularly those targeting the central nervous system.
* The isopropyl group attached to the nitrogen can influence how the molecule interacts with proteins and receptors.
* This combination of features could make this compound a candidate for studying its potential as a **psychoactive drug**, **antidepressant**, or **analgesic**.
* **Organic Chemistry:**
* This molecule can serve as a starting point for synthesizing related compounds with variations in the substituents on the phenyl ring or the cyclopentane ring.
* Researchers could study its **reaction chemistry**, exploring how it behaves under different conditions and with different reagents.
* **Materials Science:**
* The presence of the cyclopentane ring and the phenyl ring with methoxy groups could contribute to **interesting physical properties** like hydrophobicity, crystallinity, or self-assembly behavior.
**Important Note:** It's crucial to remember that the importance of a compound is determined by its specific properties and how it interacts with other molecules. The potential applications mentioned above are based on its structural features, but further research is required to confirm its actual biological activity, reactivity, or other properties.
If you have specific research goals in mind, it's best to consult with a chemist or a researcher specializing in your field for further information on this compound's potential relevance.
ID Source | ID |
---|---|
PubMed CID | 972560 |
CHEMBL ID | 1469360 |
CHEBI ID | 112885 |
Synonym |
---|
MLS000064695 |
smr000077478 |
1-(3,4-dimethoxyphenyl)-n-isopropylcyclopentanecarboxamide |
CHEBI:112885 |
1-(3,4-dimethoxyphenyl)-n-propan-2-ylcyclopentane-1-carboxamide |
HMS2459L12 |
CHEMBL1469360 |
Q27193348 |
1-(3,4-dimethoxyphenyl)-n-propan-2-yl-1-cyclopentanecarboxamide |
SR-01000280567-1 |
sr-01000280567 |
Class | Description |
---|---|
dimethoxybenzene | Any methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 39.8107 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 112.2020 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 2.8184 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |